A recent report by FirstView looks at the medical affairs support for 13 brand migraine medications, including Aimovig, Ajovy, Amerge and Axert.
“Clinicians treating migraine need the ongoing support of medical affairs teams to ensure complete knowledge of a product’s clinical value and use,” a description of the report states. “The quality of a medical affairs team’s response and service is critical in supporting prescribing and treatment decisions, so how do front-line physicians rate the service they get and where do they see room for improvement?”
To find out more about this report from FirstView, click here.
